Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy
Advertisement

Related Content

Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
Desloratadine Patent Claims No Bar To Generic Claritin, Judge Says
Schering OTC Claritin Launch May Await Loratadine Patent Dispute Resolution
Claritin OTC Approval For CIU Would Reduce Off-Label Drug Use – Schering
Loratadine Clinical Trials On General Hives Suggested By NDAC Members
Sales & Earnings In Brief
Sales & Earnings In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

PS094693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel